Document is current
Any future updates will be listed below
-
Authors
Speelberg, DHB
Peerbolte, TF
Kapelle, WM
van der Heijden, C
Bloem, BR
Post, B
Meinders, MJ
- License Information
-
More Information
Article History
Received: 14 October 2025
Accepted: 19 March 2026
First Online: 4 April 2026
Competing interests
: Prof. BR Bloem serves as the co-Editor in Chief for the Journal of Parkinson’s disease, serves on the editorial board of Practical Neurology and Digital Biomarkers, has received fees from serving on the scientific advisory board for the Critical Path Institute, Gyenno Science, MedRhythms, UCB, Kyowa Kirin and Zambon (paid to the Institute), has received fees for speaking at conferences from AbbVie, Bial, Biogen, GE Healthcare, Oruen, Roche, UCB and Zambon (paid to the Institute), and has received research support from Biogen, Cure Parkinson’s, Davis Phinney Foundation, Edmond J. Safra Foundation, Fred Foundation, Gatsby Foundation, Hersenstichting Nederland, Horizon 2020, IRLAB Therapeutics, Maag Lever Darm Stichting, Michael J Fox Foundation, Ministry of Agriculture, Ministry of Economic Affairs & Climate Policy, Ministry of Health, Welfare and Sport, Netherlands Organization for Scientific Research (ZonMw), Not Impossible, Parkinson Vereniging, Parkinson’s Foundation, Parkinson’s UK, Stichting Alkemade-Keuls, Stichting Parkinson NL, Stichting Woelse Waard, Health Holland/Topsector Life Sciences and Health, UCB, Verily Life Sciences, Roche and Zambon. Prof. BR Bloem does not hold any stocks or stock options with any companies that are connected to Parkinson’s disease or to any of his clinical or research activities. DHBS., TFP, WMK, CvdH, BP, and MJM declare no competing interests.
